Freeline Therapeutics Ltd. has topped up an original series C financing with a further $80m from specialist global institutional investors for a total of $120m. This will give the gene therapy specialist an extended financial runway for advancing its lead program in hemophilia B into a pivotal trial next year and its Phase I/II clinical program for Fabry disease as well as progressing its pipeline for Gaucher disease and hemophilia A, the UK-based group’s CEO told Scrip.
The augmented series C round was led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

